OTCM
INNMF
Market cap28mUSD
Oct 19, Last price
0.05
Name
Amplia Therapeutics Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
37.46%
Rev. 5Y
144.97%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
-100.00%
Net income
-8m
L+17.27%
CFO
-9m
L+26.83%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Key people
Hamish George
Chief Financial Officer · since 2021
Mark Devlin
Chief Scientific Officer · since 2020
Christopher Burns
Chief Executive Officer, Managing Director, Director · since 2022
Company Secretary · since 2020
Warwick Tong
Non-Executive Independent Chairman of the Board · since 2021
Non-Executive Independent Director · since 2021
Robert Peach
Non-Executive Independent Director · since 2021
IPO date
Dec 23, 2013
Employees
1
Domiciled in
AU
Incorporated in
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||